secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-040453
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi enters $75M at-the-market equity distribution agreement with Jefferies
--------------------------------------------------------------------------------

- Agreement with Jefferies to sell up to $75M of common stock via ATM offerings on Nasdaq.
- Company is not obligated to sell any shares; sales are at Metagenomi's sole discretion.
- Jefferies will receive a commission of up to 3.0% of gross proceeds from shares sold.
- Shares to be offered under a new S-3 registration statement filed March 17, 2025.
- No specific use of proceeds disclosed; proceeds may fund operations or R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025040453/0000950170-25-040453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025040453/mgx-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer